The global psoriasis market is estimated to grow significantly during the forecast period. Psoriasis is a genetic condition in which skin cells build up and form scales and itchy, dry patches. It is also considered an immune system problem, that causes rashes on the skin. The primary treatment for psoriasis is medications, that aim to eliminate scales and prevent skin cells from growing rapidly. Topical ointments, light therapy, and medication can also offer relief in psoriasis itchiness. 

The primary factors that drive the growth of the market include the increased incidences of psoriasis cases across the globe. As per the National Psoriasis Foundation in 2020, more than 8 million Americans suffer from psoriasis. According to the World Psoriasis Day consortium, globally 125 million people that is more than 3% of the total population suffers from psoriasis. Further, the increasing disease burden and demand for psoriasis medicines along with the rapid R&D activities in psoriasis research and pipeline drugs are some of the factors supporting the growth of the market. 

Moreover, the crucial factor includes the availability of advanced treatment methods. For instance, the integration of biologics with the drugs for the treatment of psoriasis is also gaining traction. Biologics are those drugs that target only specific parts of the immune system and provides better management and control on the symptoms of psoriasis. Being effective in the treatment of moderate to severe cases of psoriasis, biologics is projected to gain traction during the forecast period and hence will enhance the growth of the market globally.

Segmental Outlook

The global psoriasis market is segmented on the basis of drug class and route of administration. Based on the drug class, the market is segmented into TNF inhibitors, interleukin inhibitors, vitamin D analogs, and others. Based on the route of administration, the market is segmented into oral, parenteral, and topical. Amongst the route of administration, the topical segment is likely to hold a significant share in the market. 

Global Psoriasis Drugs Market by Route of Administration, 2018 (%)

Topical Segment to Hold Most Significant Share in the Market

Amongst the route of the administration segment of the market, the topical segment contributes a considerable share to the market growth. The segmental growth is attributed to the increased preferences of the patients for this route of administration. Some medications may lead to particular side effects whereas, the topical ointments target a specific part; and in cases of light to moderate psoriasis stages, the topical ointments are mostly preferred. Topical corticosteroids are considered as an effective treatment. Thus, this is likely to drive the segmental growth of the market. 

Regional Outlook

The global psoriasis drugs market is geographically segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to hold a significant share in the global market during the forecast period. The regional growth is attributed to the footprints of larger key players along with the large pool of patients in the region. Further, Asia-Pacific is expected to grow considerably in the market, as China contributes significantly in the market growth attributed to the several government norms such as Healthy China 2020. In addition, there is a large consumer base with strong unmet clinical needs in the region, which is likely to flourish the regional growth of the market. 

Global Psoriasis Drugs Market, by Region 2018 (%)

Market Players Outlook

Numerous major players are operating in the global psoriasis drugs industry. It is a challenging market for the new players, as MNCs have dominated the market share. The prominent players operating in the global psoriasis drugs market include AbbVie, Inc., Amgen Inc., Eli Lilly and Co., Johnson & Johnson Services Inc., Novartis International AG, AstraZeneca Plc, Boehringer Ingelheim International GmbH, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., and others. 

These are the key companies adopting several organic and inorganic growth strategies such as product launches & developments, partnerships, agreements, and acquisitions to strengthen their product portfolios and maintain a competitive position in the global Psoriasis Drugs market. For instance, in April 2019, Novartis AG introduced Cosenty, the first-in-class interleukin-17A (IL-17A) inhibitor for the treatment of modest to severe plaque psoriasis. Such launches by the key players are likely to enhance industry growth during the forecast period.

The Report Covers

• Market value data analysis of 2018 and forecast to 2025.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global Psoriasis Drugs market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.